Seigo Izumo is the Global Head of Cardiovascular Research for the Novartis Institutes for BioMedical Research (NIBR).
 

Seigo has significant experience in both clinical and basic research cardiology and in overseeing large multidisciplinary programs in this area. Prior to joining Novartis in August 2003, he had served as Professor of Medicine at Harvard Medical School in Boston and at Harvard-MIT Division of Health Sciences and Technology. In addition to his academic position at Harvard, Seigo was Director of Cardiovascular Research and Physician, Department of Medicine, Beth Israel Deaconess Medical Center, Boston and Director of the CardioGenomics Program. Previously, he was Chief of the Cardiology Division and Professor of Internal Medicine and Biological Chemistry, University of Michigan Medical School in Ann Arbor. Seigo received his undergraduate and medical degrees from the University of Tokyo, and undertook postdoctoral clinical training in internal medicine at Beth Israel Hospital, Boston, a clinical fellowship in cardiovascular disease at Beth Israel Hospital and a research fellowship in molecular biology at Howard Hughes Medical Institute, Children's Hospital, Boston.
 

Seigo Izumo's research focuses on the molecular and genetic basis of cardiac biology and pathology. He has made several fundamental contributions to such areas as the genetic response of the heart to mechanical stress, signal transduction of cardiac hypertrophy, signaling mechanisms of angiotensin II, mechanisms of heart failure, myocardial gene regulation in hypertrophy (the 'fetal gene' program), molecular mechanisms of thyroid hormone actions on the heart, genetic controls of heart development and congenital heart disease, and the effects of fluid shear stress on vascular endothelium.